Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000550574 | SCV000630738 | uncertain significance | Mucolipidosis type IV | 2022-03-18 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 338 of the MCOLN1 protein (p.Arg338Gln). This variant is present in population databases (rs368837514, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with MCOLN1-related conditions. ClinVar contains an entry for this variant (Variation ID: 459177). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The glutamine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002377035 | SCV002625017 | uncertain significance | Inborn genetic diseases | 2023-10-10 | criteria provided, single submitter | clinical testing | The c.1013G>A (p.R338Q) alteration is located in exon 9 (coding exon 9) of the MCOLN1 gene. This alteration results from a G to A substitution at nucleotide position 1013, causing the arginine (R) at amino acid position 338 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000550574 | SCV001461395 | uncertain significance | Mucolipidosis type IV | 2018-05-01 | no assertion criteria provided | clinical testing |